Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Generative AI in Clinical Trials Market to Hit USD 1,986.53 Billion by 2035 – SNS Insider

globenewswire.com
IQV IQVIA is mentioned as a market participant in the Generative AI in Clinical Trials market, indicating potential involvement and opportunity in this growing sector. ORCL Oracle Health is identified as a market participant, implying its contribution to the Generative AI in Clinical Trials sector, benefiting from the market's expansion. MSFT Microsoft is listed as a market participant, suggesting its involvement and potential to benefit from the growth in Generative AI applications within clinical trials. GOOG Google is mentioned as a company covered in the report, indicating its role and potential growth in the Generative AI in Clinical Trials market. AMZN AWS (Amazon Web Services) is listed as a market participant, implying its contribution to the Generative AI in Clinical Trials sector through cloud solutions. NVDA NVIDIA is mentioned as a key player, indicating its role in providing the AI infrastructure and processing power crucial for the Generative AI in Clinical Trials market. VEEV Veeva Systems is mentioned as a company covered in the report, indicating its presence and potential growth within the Generative AI in Clinical Trials market. IBM IBM is listed as a market participant, suggesting its involvement in the Generative AI in Clinical Trials market and potential to benefit from the sector's growth. INSM Insilico Medicine is mentioned as a company covered in the report, indicating its role and potential growth in the Generative AI in Clinical Trials market. RXRX Recursion Pharmaceuticals is listed as a market participant, suggesting its involvement and potential to benefit from the expansion of Generative AI in clinical trials.

Generative AI in Clinical Trials Market to Hit USD 1,986.53 Billion by 2035 – SNS Insider Austin, United States, Aug. 13, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Generative AI in Clinical Trials Market was valued at USD 245.82 billion in 2025 and is projected to reach USD 1,986.53 billion by 2035, expanding at a CAGR of 23.27% from 2026 to 2035.

The market is gaining commercial momentum as pharmaceutical and biotechnology companies, contract research organizations, and clinical research stakeholders increasingly evaluate generative AI platforms for patient recruitment, clinical trial design, protocol optimization, documentation, data analysis, and trial monitoring. Demand for scalable AI solutions is creating opportunities across cloud-based deployments and specialized clinical development applications.

Download the Generative AI In Clinical Trials Market Sample Report: https://www.snsinsider.com/sample-request/10495

Key Market Insights:

Generative AI Adoption in Clinical Trials Accelerates as Pharma Companies Seek Faster Development

Generative AI is becoming an option for pharmaceutical and biotechnology companies in the process of conducting clinical trials for designing protocols, recruiting patients, documenting the clinical process, analyzing data, and monitoring clinical trials. The increasing complexity of clinical research, high cost of development, and necessity to boost efficiency are driving the need for AI-driven platforms to process huge amounts of data and aid decision making.

Regional Insights:

North America led the world in terms of market share in 2025, generating about 31.29% of total revenues in the world, owing to investments made in drug discovery R&D, digital transformation of healthcare, and widespread use of technologies based on artificial intelligence. The already developed technological ecosystem in the healthcare sector and collaboration between life science organizations and AI companies further facilitate the use of AI in clinical studies.

The U.S. Generative AI in Clinical Trials Market was valued at approximately USD 62.50 Billion in 2025 and is projected to reach approximately USD 400.20 Billion by 2035, growing at a CAGR of 20.4% from 2026 to 2035. The market is driven by the growing demand for faster and cost-effective drug development processes in the pharmaceutical and biotechnology industries.

The size of Europe Generative AI in Clinical Trials Market is forecast to be around USD 66.37 Billion in 2025 and will increase to USD 521.04 Billion by 2035, at a CAGR of around 22.87% in 2026-2035. The Europe Generative AI in Clinical Trials Market is experiencing high growth due to increasing investments in digital infrastructure along with increasing adoption of artificial intelligence in the pharmaceutical development process, backed by collaborations among the research institutions, healthcare organizations, and technology providers in the region.

The Asia-Pacific market is anticipated to grow at the highest rate throughout the forecast period on account of the increasing pharmaceutical research, increased digitization of healthcare and increasing investment in artificial intelligence technology. The clinical research organizations as well as the pharmaceutical companies are making use of AI enabled platforms in order to make the process more efficient and faster.

Segmentation Analysis:

By Deployment Mode

Cloud-Based Solutions accounted for roughly 63.40% of the market in 2025, owing to scalability, reduced infrastructure costs, and capability to manage significant amounts of data pertaining to clinical and patients. The "Hybrid Deployment" category is the most promising one, growing at the highest pace due to increasing privacy and cybersecurity challenges leading companies to keep control over their patients' data.

By Application

Patient Recruitment & Matching started the race with a market share of about 34.80% in 2025 owing to AI’s capacity to handle huge amounts of data from patients and clinical settings in a time-efficient manner while also fostering real-time collaboration among global research centers. Clinical Trial Design & Protocol Optimization is the fastest growing application owing to increased demand for AI-based simulation solutions.

By End User

Pharmaceutical & Biotechnology Companies held the largest market share with nearly 52.60% in 2025, owing to high investments in generative AI to make the clinical development process more effective, lower the trial expenses, and speed up the regulatory approvals. Contract Research Organizations constitute the fastest-growing end-user category on account of an increasing trend toward outsourcing of the clinical trial activities.

By Trial Phase

Phase III Trials lead with about 39.20% market share in 2025, characterized by large patient numbers, high operational intricacies, and high costs that necessitate an efficient process for recruiting patients and managing data. Phase I Trials are the most rapidly growing trials due to the extensive use of artificial intelligence simulations for analyzing potential medicines.

Access the Complete Generative AI In Clinical Trials Market Report: https://www.snsinsider.com/reports/generative-ai-in-clinical-trials-market-10495

Leading Market Players Listed in this Report are:

Recent Developments:

Frequently Asked Questions (FAQs):

Q: What is the size of the Generative AI in Clinical Trials Market in 2025?

A: According to SNS Insider, the market was valued at USD 245.82 billion in 2025.

Q: What is the projected Generative AI in Clinical Trials Market size by 2035?

A: The market is projected to reach USD 1,986.53 billion by 2035, according to SNS Insider.

Q: What is the CAGR of the Generative AI in Clinical Trials Market?

A: The market is expected to expand at a CAGR of 23.27% from 2026 to 2035.

Q: Which segment leads the Generative AI in Clinical Trials Market?

A: Cloud-Based Solutions led by deployment mode with approximately 63.40% market share in 2025, while Patient Recruitment & Matching led by application with approximately 34.80%.

Q: Which region is expected to grow fastest?

A: Asia Pacific is expected to register the fastest growth during the forecast period, supported by expanding pharmaceutical research, healthcare digitalization, and investment in AI technologies.

Q: Which companies are covered in the Generative AI in Clinical Trials Market report?

A: The report covers companies including IQVIA, Medidata Solutions, Oracle Health, Tempus AI, Microsoft, Google, AWS, NVIDIA, SAS Institute, Veeva Systems, IBM, Insilico Medicine, Recursion Pharmaceuticals, and other market participants.

Buy the Generative AI In Clinical Trials Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/10495

Generative AI In Clinical Trials Market Report Scope

Recently Published Press Releases

Medical Spa Market Size To Exceed $92.84 Billion By 2035

Chronic Disease Management Market Size To Exceed $22.6 Billion By 2035

Prefilled Syringes Market Size To Exceed USD 29.3 Billion By 2035

Infection Control Market Size To Exceed $503.7 Billion By 2035

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.